2HANIFIN J M,THURSTON M,OMOTO M,et al. The eczema area and severity index (EASI) : assessment of reliability in atopic dermatitis. EASI Evaluator Group[J]. Exp Dermatol,2001,10(1 ) : 11 - 18.
4LING M R. Topical tacrolimus and pimecrolimus : future directions[J].Semin Cutan Med Surg,2001,20(4) :268 - 274.
5BECK L A. The efficacy and safety of tacrolimus ointment : a clinicalreview[ J]. J Am Acad Dermatol, 2005, 53 ( Suppl 2) :S165 - S170.
6Braza TJ, DiCarlo JB, Soon SL, et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol, 2003, 148(6): 1242-1244.
7Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol, 2003, 49( 1 ): 145-147.
8Nakagawa H, Etoh T, Yokota Y, et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest, 1996, 12: 245-250.
9Sugita T, Tajima M, Ito T, et al. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol, 2005, 43(6): 2824-2829.
10Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol, 2002, 46(2): 228-241.
